Skip to main content
. 2022 Apr 4;182(6):592–602. doi: 10.1001/jamainternmed.2022.0605

Figure 1. ASCEND-ID Study Design.

Figure 1.

Although investigators and patients were aware of the allocated treatment, the sponsor and steering committee remained blind to aggregate treatment assignment throughout the trial. ESA indicates erythropoiesis-stimulating agent; Hb, hemoglobin; IV, intravenous; rhEPO, recombinant human erythropoietin; SC, subcutaneous; and TSAT, transferrin saturation.

aLimited use was defined as no more than 6 weeks of short-acting ESA (rhEPO or biosimilars; maximum of 20 000 U total) or long-acting ESA (darbepoetin alfa [maximum of 100 μg total] or methoxy polyethylene glycol-epoetin beta [maximum of 125 μg total]) received before or after starting dialysis.

bSI conversion factor: To convert hemoglobin to grams per liter, multiply by 10.0.

cSI conversion factor: To convert ferritin to micrograms per liter, multiply by 1.0.